# Mapi Pharma

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/mapi-pharma

- Industry: Pharmaceuticals
- Headquarters: Israel
- Website: www.mapi-pharma.com
- Total disclosed funding: $10M
- Latest round: Series A (May 27, 2015)
- Investors on record: 1

## About

Mapi Pharma Ltd. is an innovative biopharmaceutical company specializing in the development of long-acting injectable treatments for chronic conditions such as multiple sclerosis and neuropathic pain.Founded in 2008 and headquartered in Israel, Mapi Pharma Ltd. focuses on developing advanced pharmaceuticals. The company raised USD 10 mn in a financing round led by aMoon Partners on August 17, 2017. Mapi Pharma has successfully completed 2 deals since its inception, further establishing its presence in the biopharmaceutical industry.Mapi Pharma Ltd. specializes in the development and manufacture of innovative long-acting depot injectable pharmaceuticals, primarily targeting conditions such as multiple sclerosis (MS) and neuropathic pain. The company's lead product, Glatiramer Acetate (GA) Depot, is a once-monthly intramuscular injection designed to treat various forms of MS, addressing a significant market valued at approximately USD 20 bn. Additionally, Mapi Pharma is advancing other formulations such as long-acting Pregabalin for pain management, as well as Paliperidone Palmitate and Buspirone ER for treating schizophrenia. These products are aimed at enhancing patient adherence and outcomes by reducing the frequency of injections. Mapi’s products are marketed predominantly in North America and Europe, catering to healthcare providers and patients seeking effective treatments for chronic conditions.Revenue generation for Mapi Pharma is largely driven through partnerships and business-to-business transactions with healthcare providers and pharmaceutical distributors. The transactions typically involve the sale of its flagship products, including GA Depot and Pregabalin ER, through established distribution networks that supply hospitals and clinics. Pricing structures are typically determined based on contracts with healthcare institutions and pharmaceutical wholesalers, facilitating bulk purchasing agreements and tiered pricing that reflect order volumes. Mapi Pharma operates on a model that emphasizes long-term relationships with clients, allowing for predictable revenue streams as products are integrated into treatment protocols for chronic illness management.Mapi Pharma plans to leverage the USD 10 mn raised in its latest funding round to advance its product pipeline and expand market reach. The company is currently developing new formulations, including long-acting versions of Pregabalin, with plans for launch in the next 24 months. Mapi Pharma is targeting expansion into additional European markets to increase its footprint by 2025, aiming to deliver on its commitment to enhance treatment options for patients with chronic conditions.

## Funding rounds

- Series A, May 27, 2015, $10M — Shavit Capital

## Investors

- Shavit Capital (https://capitalatlas.ai/funds/shavit-capital) — Series A